Last updated: February 23, 2026
What is the Drug Identified by NDC 25021-0751?
NDC 25021-0751 corresponds to Vasopressin Injection. It is a synthetic form of vasopressin, a hormone used primarily for vasodilatory shock, diabetes insipidus, and other emergency volume-regulating conditions. The drug is available in various formulations but primarily administered via injection.
Current Market Landscape
Market Size and Demand
- Global vasopressin market size was valued at approximately $140 million in 2022.
- Expected compound annual growth rate (CAGR) between 2022-2027: roughly 4.5%.
- Key drivers include its critical role in intensive care units (ICUs) and emergency treatment protocols.
Key Players and Product Availability
- Major manufacturers include Ferring Pharmaceuticals, Apotex, Novelion Therapeutics, and generic producers.
- Ferring markets VASOSTRICT™ (Vasopressin Injection) in the US.
- Multiple generics are available, contributing to competitive pricing.
Clinical Usage and Regulatory Status
- Approved indications include vasodilatory shock, bradycardia, and diabetes insipidus.
- FDA-approved, unexpired patent rights for original formulations.
- Off-label use includes septic shock management.
Pricing Landscape
Current List Prices
| Product |
Price per Single Use (USD) |
Notes |
| VASOSTRICT™ (Brand) |
$45 per 1 mL vial |
FDA approved; branded product |
| Generics |
$8 - $15 per 1 mL vial |
Multiple manufacturers; price range varies |
Reimbursement and Contract Pricing
- Medicaid and Medicare reimbursements tend to be lower than list prices.
- Negotiated prices often range between 30-50% discount on list prices, depending on contractual agreements.
Price Trends
- Generic prices have declined 10-20% over last three years.
- Patent expirations and increased generic competition exert downward pressure.
Future Price Projections
Assumptions for Projections
- Continued adoption of generics and biosimilars.
- Stable regulatory environment with no major patent sunsetting.
- No significant shifts in healthcare policies impacting pricing.
Short-Term (1-2 years)
- Generic prices likely to remain stable or decline slightly.
- Average price for a single 1 mL vial projected between $6 and $12.
- Branded product remains at approximately $45, potentially decreasing with biosimilar competition.
Medium-Term (3-5 years)
- Increased generic market share could push prices downward by an additional 15-25%.
- Price for 1 mL vial expected to stabilize near $5-$8.
- Possible introduction of biosimilars could further drive down prices.
Long-Term (5+ years)
- Prices could settle around $4-$8 per vial with widespread generic adoption.
- Reimbursement policies and healthcare reforms could alter pricing margins.
Market Entry Considerations
- Entry of biosimilars or new formulations could alter competitive dynamics.
- Regulatory pathways for biosimilars may reduce development costs and time.
- Price erosion is likely driven by market saturation with generics.
Key Takeaways
- Valve for vasopressin injection remains steady with significant generic competition.
- Current price per vial is approximately $8-$15 for generics, with branded at $45.
- Short-term prices will likely stabilize; medium-term prices will trend downward.
- Market growth is moderate at 4.5% CAGR, driven by ICU and emergency use.
- Patent expirations and biosimilar development are key factors influencing future prices.
FAQs
Q1: Will branded vasopressin injections maintain their prices?
A1: Probably not; increasing generic and biosimilar competition is expected to cause reductions.
Q2: How do pricing trends compare with other hormone-based injectables?
A2: Similar injectables have experienced 10-20% price declines over recent years due to generics.
Q3: Are biosimilars in development for vasopressin?
A3: No biosimilars are currently approved, but anticipated future filings could impact pricing.
Q4: What regulatory factors could influence price changes?
A4: Patent litigation, biosimilar approval pathways, and healthcare policy shifts impact prices.
Q5: How does market demand influence future pricing?
A5: Stable ICU use sustains demand, but increased generic penetration exerts downward pressure on prices.
References
- MarketsandMarkets. (2022). Vasopressin Market Insights. https://www.marketsandmarkets.com
- IQVIA. (2023). US Drug Pricing and Utilization Data.
- FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
- GoodRx. (2023). Drug Price Database.
- EvaluatePharma. (2023). Generic Drug Price Trends Report.
[1] U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
